ESR1 and cervical adenocarcinoma: 2MEBM reduced cell growth in a range of cell lines including the estrogen receptor positive breast adenocarcinoma cell line (MCF-7), prostate cancer cell line (LNACaP), estrogen receptor negative breast adenocarcinoma cell line (MDA-MB-231), human cervical adenocarcinoma cell line (HeLa) and human ovarian carcinoma (A2780) [7-12].